Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder

Abstract Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of Lewy-type synucleinopathies (LTS), which can present either with an initial predominant parkinsonism (Parkinson’s disease (PD)) or dementia (dementia with Lewy bodies (DLB)). To provide insights into th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ariadna Laguna, Helena Xicoy, Eduardo Tolosa, Mònica Serradell, Dolores Vilas, Carles Gaig, Manel Fernández, Oscar Yanes, Joan Santamaria, Núria Amigó, Alex Iranzo, Miquel Vila
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/bec3a6f30fef41dabe057654c4d8d8bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bec3a6f30fef41dabe057654c4d8d8bc
record_format	dspace
spelling	oai:doaj.org-article:bec3a6f30fef41dabe057654c4d8d8bc2021-12-02T15:43:09ZSerum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder10.1038/s41531-021-00184-92373-8057https://doaj.org/article/bec3a6f30fef41dabe057654c4d8d8bc2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41531-021-00184-9https://doaj.org/toc/2373-8057Abstract Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of Lewy-type synucleinopathies (LTS), which can present either with an initial predominant parkinsonism (Parkinson’s disease (PD)) or dementia (dementia with Lewy bodies (DLB)). To provide insights into the underlying pathogenic mechanisms, the lipoprotein and protein glycosylation profile of 82 iRBD patients, collected before and/or after their conversion to an overt LTS, and 29 matched control serum samples were assessed by nuclear magnetic resonance (NMR) spectroscopy. Data were statistically analyzed to identify altered metabolites and construct predictive models. Univariant analysis detected no differences between iRBD patients with an LTS compared to controls. However, significant differences were found when the analysis distinguished between iRBD patients that manifested initially predominant parkinsonism (pre-PD) or dementia (pre-DLB). Significant differences were also found in the analysis of paired iRBD samples pre- and post-LTS diagnosis. Predictive models were built and distinguished between controls and pre-DLB patients, and between pre-DLB and pre-PD patients. This allowed a prediction of the possible future clinical outcome of iRBD patients. We provide evidence of altered lipoprotein and glycosylation profiles in subgroups of iRBD patients. Our results indicate that metabolic alterations and inflammation are involved in iRBD pathophysiology, and suggest biological differences underlying the progression of LTS in iRBD patients. Our data also indicate that profiling of serum samples by NMR may be a useful tool for identifying short-term high-risk iRBD patients for conversion to parkinsonism or dementia.Ariadna LagunaHelena XicoyEduardo TolosaMònica SerradellDolores VilasCarles GaigManel FernándezOscar YanesJoan SantamariaNúria AmigóAlex IranzoMiquel VilaNature PortfolioarticleNeurology. Diseases of the nervous systemRC346-429ENnpj Parkinson's Disease, Vol 7, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurology. Diseases of the nervous system RC346-429 Ariadna Laguna Helena Xicoy Eduardo Tolosa Mònica Serradell Dolores Vilas Carles Gaig Manel Fernández Oscar Yanes Joan Santamaria Núria Amigó Alex Iranzo Miquel Vila Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder
description	Abstract Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of Lewy-type synucleinopathies (LTS), which can present either with an initial predominant parkinsonism (Parkinson’s disease (PD)) or dementia (dementia with Lewy bodies (DLB)). To provide insights into the underlying pathogenic mechanisms, the lipoprotein and protein glycosylation profile of 82 iRBD patients, collected before and/or after their conversion to an overt LTS, and 29 matched control serum samples were assessed by nuclear magnetic resonance (NMR) spectroscopy. Data were statistically analyzed to identify altered metabolites and construct predictive models. Univariant analysis detected no differences between iRBD patients with an LTS compared to controls. However, significant differences were found when the analysis distinguished between iRBD patients that manifested initially predominant parkinsonism (pre-PD) or dementia (pre-DLB). Significant differences were also found in the analysis of paired iRBD samples pre- and post-LTS diagnosis. Predictive models were built and distinguished between controls and pre-DLB patients, and between pre-DLB and pre-PD patients. This allowed a prediction of the possible future clinical outcome of iRBD patients. We provide evidence of altered lipoprotein and glycosylation profiles in subgroups of iRBD patients. Our results indicate that metabolic alterations and inflammation are involved in iRBD pathophysiology, and suggest biological differences underlying the progression of LTS in iRBD patients. Our data also indicate that profiling of serum samples by NMR may be a useful tool for identifying short-term high-risk iRBD patients for conversion to parkinsonism or dementia.
format	article
author	Ariadna Laguna Helena Xicoy Eduardo Tolosa Mònica Serradell Dolores Vilas Carles Gaig Manel Fernández Oscar Yanes Joan Santamaria Núria Amigó Alex Iranzo Miquel Vila
author_facet	Ariadna Laguna Helena Xicoy Eduardo Tolosa Mònica Serradell Dolores Vilas Carles Gaig Manel Fernández Oscar Yanes Joan Santamaria Núria Amigó Alex Iranzo Miquel Vila
author_sort	Ariadna Laguna
title	Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder
title_short	Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder
title_full	Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder
title_fullStr	Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder
title_full_unstemmed	Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder
title_sort	serum metabolic biomarkers for synucleinopathy conversion in isolated rem sleep behavior disorder
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/bec3a6f30fef41dabe057654c4d8d8bc
work_keys_str_mv	AT ariadnalaguna serummetabolicbiomarkersforsynucleinopathyconversioninisolatedremsleepbehaviordisorder AT helenaxicoy serummetabolicbiomarkersforsynucleinopathyconversioninisolatedremsleepbehaviordisorder AT eduardotolosa serummetabolicbiomarkersforsynucleinopathyconversioninisolatedremsleepbehaviordisorder AT monicaserradell serummetabolicbiomarkersforsynucleinopathyconversioninisolatedremsleepbehaviordisorder AT doloresvilas serummetabolicbiomarkersforsynucleinopathyconversioninisolatedremsleepbehaviordisorder AT carlesgaig serummetabolicbiomarkersforsynucleinopathyconversioninisolatedremsleepbehaviordisorder AT manelfernandez serummetabolicbiomarkersforsynucleinopathyconversioninisolatedremsleepbehaviordisorder AT oscaryanes serummetabolicbiomarkersforsynucleinopathyconversioninisolatedremsleepbehaviordisorder AT joansantamaria serummetabolicbiomarkersforsynucleinopathyconversioninisolatedremsleepbehaviordisorder AT nuriaamigo serummetabolicbiomarkersforsynucleinopathyconversioninisolatedremsleepbehaviordisorder AT alexiranzo serummetabolicbiomarkersforsynucleinopathyconversioninisolatedremsleepbehaviordisorder AT miquelvila serummetabolicbiomarkersforsynucleinopathyconversioninisolatedremsleepbehaviordisorder
_version_	1718385833402171392

Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder

Ejemplares similares